Why the Mesoblast limited share price has soared 45%

The Mesoblast limited (ASX:MSB) share price has risen another 12% today, and 45% over the last week.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of regenerative medicine group Mesoblast limited (ASX: MSB) have continued their impressive run today, climbing another 12.3% to trade at $1.69. That's a 45% improvement compared to their $1.165 closing price on Monday last week.

Source: Yahoo! Finance
Source: Yahoo! Finance

While the gains from last week can mostly be attributed to a positive earnings report and successful results for its Phase 2 rheumatoid arthritis trials, this time the gain appears to have come from results showing its stem cell treatment was helping children survive bone marrow transplants.

The results reportedly showed that the use of Mesoblast's proprietary Tier 1 mesenchymal stem cell product candidate (MSC-100-IV) demonstrated "clinically meaningful responses" and significantly increases survival in children who were suffering steroid-refractory acute Graft Versus Host Disease (aGVHD).

Basically, MSC-100-IV is intended to become a treatment for children suffering from aGVHD, which is a disease where donor cells may attack the recipient of a bone marrow transplant. The disease can then attack the skin, gut and liver and is often fatal. Mesoblast noted that: "Currently, there are no approved therapies for patients with acute steroid-refractory GVHD in the United States, and off-label options have demonstrated mixed efficacy with high toxicity."

But based on the trial's results, the study's lead investigator Dr Joanne Kurtzberg said that "we are now seeing the majority of children who receive Mesoblast's cell therapy respond and survive."

The study observed 241 children suffering the disease and the company reported a response rate of 81% seen when MSC-100-IV was used as front-line therapy following steroid failure. Further trials will be conducted, but today's results were certainly encouraging for investors.

Should you buy?

Shareholders of Mesoblast could be very well rewarded in the long run if it can continue to report successful trials results, and if it can continue to get by on the cash that it has (rather than raising even more capital from equity markets).

In saying that, it is also a risky bet. The development and trials of new products can be extremely time consuming and if they prove to be failures it can result in sharp falls in the share price.

As has been the case for shareholders of Sirtex Medical Limited (ASX: SRX), Mesoblast could also be a reasonable bet for long-term investors, but those who are less tolerant to risk may want to steer clear.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »